Abeona reports Q2 net income of $108.8M on PRV sale; ZEVASKYN launch on track

ABEONA THERAPEUTICS INC.

2025-Q2 EPS reported $1.47 vs consensus -$0.39 ▲ beat (+477.6%)

Net income $108.8M ($2.07 basic EPS) vs $7.4M in Q2 2024; includes $155M gain from PRV sale.
Cash $225.9M expected to fund operations over two years without anticipated ZEVASKYN revenue.
First ZEVASKYN patient treatment expected in Q3 2025; multiple patients identified at QTCs.
100% of prior authorization requests approved; United Healthcare issued favorable coverage policy.
R&D expense fell to $5.9M; SG&A rose to $17.1M due to commercial launch costs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.